Long-term safety and efficacy of COVE study open-label and booster phases
Abstract Vaccination with two injections of mRNA-1273 (100-μg) was shown to be safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the Coronavirus Efficacy (COVE) trial at completion of the blinded part of the study. We present the final report of the longer-term safety and efficacy data of the primary vaccination series plus a 50-μg booster dose administered in Fall 2021. The booster safety profile was consistent with that of the primary series. Incidences of COVID-19 and severe COVID-19 were higher during the Omicron BA.1 than Delta variant waves and boosting versus non-boosting was associated with significant reductions for both. In an exploratory Cox regression model adjusted for time-varying covariates, a longer interval between primary vaccination and boosting was associated with a significantly lower incidence of COVID-19 during the Omicron BA.1 wave. Boosting elicited greater immune responses against ancestral SARS-CoV-2 than the primary series, irrespective of prior SARS-CoV-2 infection. ClinicalTrials.gov: NCT04470427.
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ResearchSquare.com - (2024) vom: 14. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baden, Lindsey [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-3900939/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA04292023X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA04292023X | ||
| 003 | DE-627 | ||
| 005 | 20240315131128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3900939/v1 |2 doi | |
| 035 | |a (DE-627)XRA04292023X | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-3900939/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baden, Lindsey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term safety and efficacy of COVE study open-label and booster phases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Vaccination with two injections of mRNA-1273 (100-μg) was shown to be safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the Coronavirus Efficacy (COVE) trial at completion of the blinded part of the study. We present the final report of the longer-term safety and efficacy data of the primary vaccination series plus a 50-μg booster dose administered in Fall 2021. The booster safety profile was consistent with that of the primary series. Incidences of COVID-19 and severe COVID-19 were higher during the Omicron BA.1 than Delta variant waves and boosting versus non-boosting was associated with significant reductions for both. In an exploratory Cox regression model adjusted for time-varying covariates, a longer interval between primary vaccination and boosting was associated with a significantly lower incidence of COVID-19 during the Omicron BA.1 wave. Boosting elicited greater immune responses against ancestral SARS-CoV-2 than the primary series, irrespective of prior SARS-CoV-2 infection. ClinicalTrials.gov: NCT04470427 | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Sahly, Hana El |0 (orcid)0000-0003-0489-0074 |4 aut | |
| 700 | 1 | |a Essink, Brandon |4 aut | |
| 700 | 1 | |a Follmann, Dean |0 (orcid)0000-0003-4073-0393 |4 aut | |
| 700 | 1 | |a Hachigian, Gregory |4 aut | |
| 700 | 1 | |a Strout, Cynthia |4 aut | |
| 700 | 1 | |a Overcash, J. Scott |4 aut | |
| 700 | 1 | |a Doblecki-Lewis, Susanne |4 aut | |
| 700 | 1 | |a Whitaker, Jennifer |4 aut | |
| 700 | 1 | |a Anderson, Evan |0 (orcid)0000-0002-1576-4420 |4 aut | |
| 700 | 1 | |a Neuzil, Kathleen |0 (orcid)0000-0001-9480-2714 |4 aut | |
| 700 | 1 | |a Corey, Lawrence |0 (orcid)0000-0002-2179-2436 |4 aut | |
| 700 | 1 | |a Priddy, Frances |4 aut | |
| 700 | 1 | |a Tomassini, Joanne |0 (orcid)0000-0002-9399-2867 |4 aut | |
| 700 | 1 | |a Brown, Mollie |4 aut | |
| 700 | 1 | |a Girard, Bethany |4 aut | |
| 700 | 1 | |a Stolman, Dina |4 aut | |
| 700 | 1 | |a Urdaneta, Veronica |4 aut | |
| 700 | 1 | |a Wang, Xiaowei |4 aut | |
| 700 | 1 | |a Deng, Weiping |4 aut | |
| 700 | 1 | |a Zhou, Honghong |4 aut | |
| 700 | 1 | |a Dixit, Avika |0 (orcid)0000-0002-8381-3298 |4 aut | |
| 700 | 1 | |a Das, Rituparna |4 aut | |
| 700 | 1 | |a Miller, Jacqueline |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2024) vom: 14. März |
| 773 | 1 | 8 | |g year:2024 |g day:14 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3900939/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 14 |c 03 | ||